ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations
All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400
Please be sure to complete the following:

Company name: New Phase Ltd Website: www.newphase.co.il

CEO name: Ofer Shalev

Select a CATEGORY: Medical Devices
(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *
(Delete sessions you are not selecting)

- Redefining the fight against Cancer: New Targets and Novel Therapeutic Modalities
- Medical Device Company: The Route from Vision to a Successful Outcome

Abstract:

- **Executive Summary/Investment Rational**

New Phase is developing a novel therapeutic approach for stage IV solid tumors based on thermal energy delivery by magnetic nanoparticles and Alternating Magnetic Field (AMF) irradiation, thereby inducing hyperthermic cancer cell death at temperatures of up to 50^0C.
The technology is aimed at treating cancer patients at metastatic stage for whom other standard treatments have been exhausted. The global market for metastatic cancer is projected to reach $127 billion by 2026.

- **Core Technology**

The technology is an FDA-designated medical device class III comprising of: 1. Proprietary magnetic nanoparticles, containing multicore encapsulated superparamagnetic iron oxide, named Sarah Nanoparticles (SaNPs), that are intravenously administered and localize on cancer cells via the Enhanced Permeability and Retention (EPR) effect and; 2. An Electromagnetic Induction System (EIS), in which the patient's torso undergoes regional non-ionizing AMF irradiation.

- **Product Profile/Pipeline**

SaNPs are composed of iron oxide nanoclusters, and a phase change material (PCM) core that enables self-control of the temperature. SaNPs are manufactured by New Phase's clean room for clinical use. Our collaborators include both medical centers and strategic partners from the interventional oncology area.

- **Business Strategy**

Following completion of early feasibility study, an institutional funding round of $20M will be completed to support a feasibility multi-center study. At the feasibility study, besides our technology as stand alone, there will be additional arms of interventional oncology based on collaboration with medical centers/strategic partners.

- **What's Next?**

The company is currently conducting a First-in-Human clinical trial at Rabin Medical Center, Israel, to evaluate the safety of the treatment in patients with advanced metastatic solid tumors. So far, 23 patients have been treated, and the treatment has been proven safe and feasible. An additional study will soon start in the US.